Journal
NATURE GENETICS
Volume 41, Issue 5, Pages 544-552Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ng.356
Keywords
-
Categories
Funding
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center Mouse Pathology and Pre-Clinical Therapeutics cores
- Melanoma Research Foundation
- U.C. Discovery Award
- US National Institutes of Health [CA 108972, CA 84313, CA 89124, CA 112054]
Ask authors/readers for more resources
Mutational activation of BRAF is the earliest and most common genetic alteration in human melanoma. To build a model of human melanoma, we generated mice with conditional melanocyte-specific expression of BRaf(V600E). Upon induction of BRaf(V600E) expression, mice developed benign melanocytic hyperplasias that failed to progress to melanoma over 15-20 months. By contrast, expression of BRaf(V600E) combined with Pten tumor suppressor gene silencing elicited development of melanoma with 100% penetrance, short latency and with metastases observed in lymph nodes and lungs. Melanoma was prevented by inhibitors of mTorc1 (rapamycin) or MEK1/2 (PD325901) but, upon cessation of drug administration, mice developed melanoma, indicating the presence of long-lived melanoma-initiating cells in this system. Notably, combined treatment with rapamycin and PD325901 led to shrinkage of established melanomas. These mice, engineered with a common genetic profile to human melanoma, provide a system to study melanoma's cardinal feature of metastasis and for preclinical evaluation of agents designed to prevent or treat metastatic disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available